Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size, Status and Forecast 2020-2026
SKU ID : QYR-15572479 | Publishing Date : 17-Apr-2020 | No. of pages : 95
Detailed TOC of Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size, Status and Forecast 2020-2026
1 Report Overview1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue
1.4 Market Analysis by Therapy
1.4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Therapy: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Radiation Therapy
1.4.4 Others
1.5 Market by End Users
1.5.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by End Users: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Industry Impact
1.6.1 How the Covid-19 is Affecting the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Industry
1.6.1.1 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends by Regions
2.1 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Perspective (2015-2026)
2.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Growth Trends by Regions
2.2.1 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Market Size
3.1.1 Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Revenue (2015-2020)
3.1.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Concentration Ratio
3.2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue in 2019
3.3 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Key Players Head office and Area Served
3.4 Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product Solution and Service
3.5 Date of Enter into Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Therapy (2015-2026)
4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Historic Market Size by Therapy (2015-2020)
4.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Therapy (2021-2026)
5 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Breakdown Data by End Users (2015-2026)
5.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020)
5.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by End Users (2021-2026)
6 North America
6.1 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2015-2020)
6.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Key Players in North America (2019-2020)
6.3 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020)
6.4 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020)
7 Europe
7.1 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2015-2020)
7.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Key Players in Europe (2019-2020)
7.3 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020)
7.4 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020)
8 China
8.1 China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2015-2020)
8.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Key Players in China (2019-2020)
8.3 China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020)
8.4 China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020)
9 Japan
9.1 Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size (2015-2020)
9.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Key Players in Japan (2019-2020)
9.3 Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020)
9.4 Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020)
10Key Players Profiles
10.1 Roche
10.1.1 Roche Company Details
10.1.2 Roche Business Overview and Its Total Revenue
10.1.3 Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.1.4 Roche Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020))
10.1.5 Roche Recent Development
10.2 Novartis
10.2.1 Novartis Company Details
10.2.2 Novartis Business Overview and Its Total Revenue
10.2.3 Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.2.4 Novartis Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
10.2.5 Novartis Recent Development
10.3 Seattle Genetics
10.3.1 Seattle Genetics Company Details
10.3.2 Seattle Genetics Business Overview and Its Total Revenue
10.3.3 Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.3.4 Seattle Genetics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
10.3.5 Seattle Genetics Recent Development
10.4 Merck
10.4.1 Merck Company Details
10.4.2 Merck Business Overview and Its Total Revenue
10.4.3 Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.4.4 Merck Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
10.4.5 Merck Recent Development
10.5 Bristol-Myers Squibb
10.5.1 Bristol-Myers Squibb Company Details
10.5.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
10.5.3 Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.5.4 Bristol-Myers Squibb Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
10.5.5 Bristol-Myers Squibb Recent Development
10.6 Genmab AS
10.6.1 Genmab AS Company Details
10.6.2 Genmab AS Business Overview and Its Total Revenue
10.6.3 Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.6.4 Genmab AS Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
10.6.5 Genmab AS Recent Development
10.7 Takeda Pharmaceutical
10.7.1 Takeda Pharmaceutical Company Details
10.7.2 Takeda Pharmaceutical Business Overview and Its Total Revenue
10.7.3 Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.7.4 Takeda Pharmaceutical Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
10.7.5 Takeda Pharmaceutical Recent Development
10.8 Eisai Co., Ltd.
10.8.1 Eisai Co., Ltd. Company Details
10.8.2 Eisai Co., Ltd. Business Overview and Its Total Revenue
10.8.3 Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.8.4 Eisai Co., Ltd. Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
10.8.5 Eisai Co., Ltd. Recent Development
10.9 Cellerant Therapeutics
10.9.1 Cellerant Therapeutics Company Details
10.9.2 Cellerant Therapeutics Business Overview and Its Total Revenue
10.9.3 Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Introduction
10.9.4 Cellerant Therapeutics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
10.9.5 Cellerant Therapeutics Recent Development
11Analyst's Viewpoints/Conclusions
12Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details
List of Figures, Tables and Charts Available in Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size, Status and Forecast 2020-2026
List of TablesTable 1. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue
Table 3. Ranking of Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth Rate by Therapy (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Radiation Therapy
Table 7. Key Players of Others
Table 8. COVID-19 Impact Global Market: (Four Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players to Combat Covid-19 Impact
Table 13. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Growth by End Users (US$ Million): 2020 VS 2026
Table 14. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Regions (2015-2020)
Table 17. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Growth Strategy
Table 23. Main Points Interviewed from Key Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players
Table 24. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Players (2015-2020) (Million US$)
Table 25. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Players (2015-2020)
Table 26. Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment as of 2019)
Table 27. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product Solution and Service
Table 30. Date of Enter into Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020) (Million US$)
Table 33. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Share by Therapy (2015-2020)
Table 34. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Therapy (2021-2026)
Table 35. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Share by End Users (2015-2020)
Table 36. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020) (Million US$)
Table 37. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Share by End Users (2021-2026)
Table 38. North America Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (2019-2020) (Million US$)
Table 39. North America Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share (2019-2020)
Table 40. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020) (Million US$)
Table 41. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Therapy (2015-2020)
Table 42. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020) (Million US$)
Table 43. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by End Users (2015-2020)
Table 44. Europe Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share (2019-2020)
Table 46. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020) (Million US$)
Table 47. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Therapy (2015-2020)
Table 48. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020) (Million US$)
Table 49. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by End Users (2015-2020)
Table 50. China Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (2019-2020) (Million US$)
Table 51. China Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share (2019-2020)
Table 52. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020) (Million US$)
Table 53. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Therapy (2015-2020)
Table 54. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020) (Million US$)
Table 55. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by End Users (2015-2020)
Table 56. Japan Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (2019-2020) (Million US$)
Table 57. Japan Key Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share (2019-2020)
Table 58. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Therapy (2015-2020) (Million US$)
Table 59. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Therapy (2015-2020)
Table 60. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by End Users (2015-2020) (Million US$)
Table 61. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by End Users (2015-2020)
Table 62. Roche Company Details
Table 63. Roche Business Overview
Table 64. Roche Product
Table 65. Roche Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 66. Roche Recent Development
Table 67. Novartis Company Details
Table 68. Novartis Business Overview
Table 69. Novartis Product
Table 70. Novartis Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 71. Novartis Recent Development
Table 72. Seattle Genetics Company Details
Table 73. Seattle Genetics Business Overview
Table 74. Seattle Genetics Product
Table 75. Seattle Genetics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 76. Seattle Genetics Recent Development
Table 77. Merck Company Details
Table 78. Merck Business Overview
Table 79. Merck Product
Table 80. Merck Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 81. Merck Recent Development
Table 82. Bristol-Myers Squibb Company Details
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Product
Table 85. Bristol-Myers Squibb Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 86. Bristol-Myers Squibb Recent Development
Table 87. Genmab AS Company Details
Table 88. Genmab AS Business Overview
Table 89. Genmab AS Product
Table 90. Genmab AS Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 91. Genmab AS Recent Development
Table 92. Takeda Pharmaceutical Company Details
Table 93. Takeda Pharmaceutical Business Overview
Table 94. Takeda Pharmaceutical Product
Table 95. Takeda Pharmaceutical Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 96. Takeda Pharmaceutical Recent Development
Table 97. Eisai Co., Ltd. Business Overview
Table 98. Eisai Co., Ltd. Product
Table 99. Eisai Co., Ltd. Company Details
Table 100. Eisai Co., Ltd. Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 101. Eisai Co., Ltd. Recent Development
Table 102. Cellerant Therapeutics Company Details
Table 103. Cellerant Therapeutics Business Overview
Table 104. Cellerant Therapeutics Product
Table 105. Cellerant Therapeutics Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020) (Million US$)
Table 106. Cellerant Therapeutics Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Therapy: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Radiation Therapy Features
Figure 4. Others Features
Figure 5. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by End Users: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Ambulatory Surgical Centers Case Studies
Figure 9. Others Case Studies
Figure 10. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Report Years Considered
Figure 11. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Regions: 2020 VS 2026
Figure 13. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share by Players in 2019
Figure 16. Global Top Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue in 2019
Figure 18. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 23. Roche Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 24. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Novartis Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 26. Seattle Genetics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Seattle Genetics Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 28. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Merck Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 30. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Bristol-Myers Squibb Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 32. Genmab AS Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Genmab AS Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 34. Takeda Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Takeda Pharmaceutical Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 36. Eisai Co., Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Eisai Co., Ltd. Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 38. Cellerant Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Cellerant Therapeutics Revenue Growth Rate in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Business (2015-2020)
Figure 40. Bottom-up and Top-down Approaches for This Report
Figure 41. Data Triangulation
Figure 42. Key Executives Interviewed
Keyplayers in Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size, Status and Forecast 2020-2026
RocheNovartis
Seattle Genetics
Merck
Bristol-Myers Squibb
Genmab AS
Takeda Pharmaceutical
Eisai Co., Ltd.
Cellerant Therapeutics